Abstract:Alzheimer's disease is a neurodegenerative disorder accounting for 60–80% of dementia cases and is accompanied by a high mortality rate in patients above 70 years of age. The formation of senile plaques composed of amyloid-β protein is a hallmark of Alzheimer's disease. Beta-site APP cleaving enzyme 1 (BACE1) is a proteolytic enzyme involved in the degradation of amyloid precursor protein, which further degrades to form toxic amyloid-β fragments. Hence, inhibition of BACE1 was stated to be an effective strategy for Alzheimer's therapeutics. Keeping in mind the structures of different BACE1 inhibitors that had reached the clinical trials, we designed a library of compounds (total 164) based on a substituted 5-amino tetrazole scaffold which was an isosteric replacement of the cyclic amidine moiety, a common component of the BACE1 inhibitors which reached the clinical trials. The scaffold was linked to different structural moieties with the aid of an amide or sulfonamide bond to design some novel molecules. Molecular docking was initially performed and the top 5 molecules were selected based on docking scores and protein–ligand interactions. Furthermore, molecular dynamic simulations were performed for these molecules ( 3g , 7k , 8n , 9d , 9g ) for 100 ns and MM-GBSA calculations were performed for each of these complexes. After critical evaluation of the obtained results, three potential molecules ( 9d , 8n , and 7k ) were forwarded for prolonged stability studies by performing molecular dynamic simulations for 250 ns and simultaneous MM-GBSA calculations. It was observed that the compounds ( 9d , 8n , and 7k ) were forming good interactions with the amino acid residues of the catalytic site of the enzyme with multiple non-covalent interactions. In MD simulations, the compounds have shown better stability and better binding energy throughout the runtime.

Structure-based design and synthesis of novel P2/P3 modified, non-peptidic β-secretase (BACE-1) inhibitors

Structure-based design and synthesis of novel P2/P3 modified, non-peptidic beta-secretase (BACE-1) inhibitors.

Design, Synthesis and Evaluation of 3-(2-aminoheterocycle)-4-benzyloxyphenylbenzamide Derivatives As BACE-1 Inhibitors

Structure-Based Design of an Iminoheterocyclic β-Site Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor that Lowers Central Aβ in Nonhuman Primates.

Structure-Based Design Of An Iminoheterocyclic Beta-Site Amyloid Precursor Protein Cleaving Enzyme (Bace) Inhibitor That Lowers Central A Beta In Nonhuman Primates

Synthesis and Preliminary Evaluation of Peptidomimetic Inhibitors of Human Beta-Secretase

Design And Validation Of Bicyclic Iminopyrimidinones As Beta Amyloid Cleaving Enzyme-1 (Bace1) Inhibitors: Conformational Constraint To Favor A Bioactive Conformation

Dual-target-directed 1,3-Diphenylurea Derivatives: BACE 1 Inhibitor and Metal Chelator Against Alzheimer’s Disease

2-Substituted-thio-n-(4-substituted-thiazol/1h-imidazol-2-yl)acetamides As BACE1 Inhibitors: Synthesis, Biological Evaluation and Docking Studies.

Discovery and optimization of a novel spiropyrrolidine inhibitor of β-secretase (BACE1) through fragment-based drug design.

Progress in the Development of Nonpeptidomimetic BACE 1 Inhibitors for Alzheimers Disease

Structure-based Design of Hexahydropyrimidine-5-ols As Novel Non-Peptidic Β-Secretase Inhibitors

Identification Of Novel Bace1 Inhibitors By Combination Of Pharmacophore Modeling, Structure-Based Design And In Vitro Assay

Discovery of potent iminoheterocycle BACE1 inhibitors

Spirocyclic Sulfamides As Β-Secretase 1 (BACE-1) Inhibitors for the Treatment of Alzheimer's Disease: Utilization of Structure Based Drug Design, WaterMap, and CNS Penetration Studies to Identify Centrally Efficacious Inhibitors.

Design, Synthesis and Biological Evaluation of Novel Non-peptide Boronic Acid Derivatives As Proteasome Inhibitors

Design and Synthesis of 2-Aminobenzimidazoles As Potential BACE1 Inhibitors

4-Oxo-1,4-dihydro-quinoline-3-carboxamides as BACE-1 inhibitors: synthesis, biological evaluation and docking studies.

Structure-Based Design of Selective β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitors: Targeting the Flap to Gain Selectivity over BACE2

Sulfonamido, amido heterocyclic adducts of tetrazole derivatives as BACE1 inhibitors: in silico exploration

Piperazine Sulfonamide BACE1 Inhibitors: Design, Synthesis, and in Vivo Characterization